

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 August 2024 (02.08.2024)



(10) International Publication Number
WO 2024/158859 A1

(51) International Patent Classification:
A61K 33/00 (2006.01) A61K 45/06 (2006.01)

(21) International Application Number:
PCT/US2024/012689

(22) International Filing Date:
24 January 2024 (24.01.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/441,131 25 January 2023 (25.01.2023) US

(71) Applicant: HUYABIO INTERNATIONAL, LLC
[US/US]; 12531 High Bluff Drive, Suite 138, San Diego,
California 92130 (US).

(72) Inventors: LEE, Gloria; 12531 High Bluff Drive, Suite
138, San Diego, California 92130 (US). GILLINGS,
Mireille; 12531 High Bluff Drive, Suite 138, San Diego,
California 92130 (US).

(74) Agent: GRUMBLING, MATTHEW V.; EVERSHEDES
SUTHERLAND (US) LLP, 12255 El Camino Real, Suite
100, San Diego, California 92130 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS AND COMPOSITIONS COMPRISING A CARDIO-TOLERATED HDAC INHIBITOR




Figure 1A. Mean (±Standard Deviation) HBI-8000 Plasma Concentration-Time Profiles
CID1 = Cycle 1 Day 1; C2D1 = Cycle 2 Day 1; n = largest number of patients who provided
observations at any time point within the concentration-time profile.
Note: Values below the lower limit of quantitation of the assay were set to 0 to calculate
descriptive statistics. The lower limit of quantitation was 1.00 ng/mL.

(57) Abstract: Provided herein are methods comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor, and/or an anti-cancer agent. Also, provided herein are pharmaceutical compositions suitable for treatment of cancer.

[Continued on next page]

WO 2024/158859 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))